Endo International plc (NDOI)
OTC PINK OTC PINK Primary Summary
NDOI Chart
Endo Completes International Pharmaceuticals Business Divestiture
MALVERN, Pa. , June 17, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced that it has completed the previously announced divestiture of its International Pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc., to Knight Therapeutics Inc. Total cash consideration for the sale is up to approximately $105 million, consisting of approximately $79 million paid at closing, approximately $11 million related to certain permitted holdbacks, and up to $15 million in future payments contingent upon the achievement of certain milestones.
Endo Champions Men's Health Month with Education, Awareness, and Outreach
MALVERN, Pa. , June 2, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today its Men's Health Month initiative, reaffirming its commitment to advancing men's health and addressing health issues affecting men.
Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line with New Concentration
Endo's products are the first FDA-approved and currently the only commercially available manufacturer-prepared epinephrine premixed intravenous (IV) bag MALVERN, Pa. , May 15, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of ADRENALIN® (epinephrine in 0.9% sodium chloride injection) 8 mg/250 mL premixed bag and will begin shipping the product the week of May 19, 2025.
Endo International plc Dividends
Endo International plc Earnings
| 6 Aug 2025 (In 4 weeks) Date | | 0.5 Cons. EPS | - EPS |
| 5 Nov 2024 Date | | - Cons. EPS | - EPS |
| 27 Aug 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2025 (In 4 weeks) Date | | 0.5 Cons. EPS | - EPS |
| 5 Nov 2024 Date | | - Cons. EPS | - EPS |
| 27 Aug 2024 Date | | - Cons. EPS | - EPS |
Endo International plc (NDOI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Endo International plc ever had a stock split?
Endo International plc Profile
| Drug Manufacturers—Specialty & Generic Industry | Healthcare Sector | Mr. Blaise A. Coleman CEO | OTC PINK Exchange | - ISIN |
| United States Country | 2,931 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Endo Inc. is a specialty pharmaceutical company with a global reach, dedicated to developing, manufacturing, marketing, and selling a wide array of pharmaceutical products. Established in 1997 and based in Malvern, Pennsylvania, Endo operates across four main segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company focuses on providing high-quality products for the treatment of various conditions across urology, orthopedics, endocrinology, and other fields. Endo's approach combines expertise in specialty pharmaceuticals with a commitment to innovation and patient care, serving diverse markets in the United States and internationally.
Products and Services
-
Branded Pharmaceuticals:
Endo's Branded Pharmaceuticals segment offers innovative treatments for conditions in urology, orthopedics, and endocrinology. Notable products include XIAFLEX, a non-surgical treatment for adult men with Peyronie's Disease or Dupuytren's Contracture, offering relief in cases of abnormal collagen buildup. This segment is fervent in pursuing additional indications for XIAFLEX, including treatments for plantar fibromatosis and plantar fasciitis, as well as initiating pre-clinical developments for conditions such as arthrofibrosis of the knee.
-
Sterile Injectables:
This segment provides essential emergency and therapeutic treatments through products like ADRENALIN, for the emergency treatment of allergic reactions including anaphylaxis, and VASOSTRICT, which is used to increase blood pressure in adults experiencing vasodilatory shock who do not respond adequately to fluids and catecholamines.
-
Generic Pharmaceuticals:
Endo offers a broad portfolio of generic pharmaceuticals that include solid oral extended-release, solid oral immediate release, liquids, semi-solids, patches, powders, ophthalmics, and sprays. These products cater to a wide range of medical conditions, ensuring accessibility and affordability in healthcare treatment options.
-
International Pharmaceuticals:
Through its International Pharmaceuticals segment, Endo brings a variety of specialty pharmaceutical products primarily to the Canadian market. These products cover therapeutic areas such as attention deficit hyperactivity disorder (ADHD), pain, women's health, oncology, transplantation, and include over-the-counter products, addressing a comprehensive range of healthcare needs.
Contact Information
